Shenzhen Key Laboratory of Anti-Ageing and Regenerative Medicine, Department of Medical Cell Biology and Genetics, Guangdong Key Laboratory for Genome Stability & Disease Prevention, Shenzhen University Medical School, Shenzhen, Guangdong 518060, China; Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, Guangdong, 518060, China.
Shenzhen Engineering Laboratory of Orthopaedic Regenerative Technologies, Departments of Orthopaedics, Peking University Shenzhen Hospital, Shenzhen, Guangdong 510086, China.
Acta Biomater. 2018 Oct 1;79:202-215. doi: 10.1016/j.actbio.2018.08.029. Epub 2018 Aug 28.
Many attempts have been made to repair articular cartilage defects, including mesenchymal stem cell (MSC)-based tissue engineering strategies. Although this approach shows promise, optimizing MSC sources and their delivery is challenging. This study was designed to test the feasibility of using MSCs found in the human arthroscopic flushing fluid (AFF) for cartilage regeneration, by incorporating them into a newly developed one-step rapid cross-linking hyper-branched polyPEGDA/HA hydrogel. AFF-MSCs were isolated from the original intra-articular flushing fluid of 10 patients prior to arthroscopic procedures. The hydrogel was fabricated with hyper-branched polyPEGDA and thiolated hyaluronic acid (HA). In vitro assays demonstrated that AFF-MSCs possessed the typical MSC morphology and phenotype, and maintained chondrogenic differentiation properties when encapsulated within the hydrogel. The AFF-MSC/hydrogel composite could significantly repair full-thickness cartilage defects generated in a rat model after 8 weeks of implantation; smooth cartilage was formed with evidence of hyaline cartilage formation. These data suggest that human AFF-MSCs are a novel and abundant MSC source that have high therapeutic value for cartilage regeneration.
Many attempts have been made to repair the defects of articular cartilage, including mesenchymal stem cell (MSC)-based tissue engineering strategies. Optimizing MSC sources and their delivery approaches still remain clinically challenging. Recent studies determined that MSCs derived from synovium and synovial fluid exhibited superior chondrogenic potential. However, no feasible methods to harvest these human tissues and cells have been impeding them for clinical application. Hereby, we explored a simple and easy accessible approach to obtain a new stem cell source from arthroscopic flushing fluid (AFF-MSCs), which probably contains plenty of MSCs from synovium and synovial fluid. Further experiments demonstrated that encapsulation of these stem cells with one-step rapid cross-linked polyPEGDA/HA hydrogel held very encouraging potential for cartilage regeneration.
许多尝试已经被用来修复关节软骨缺陷,包括基于间充质干细胞(MSC)的组织工程策略。尽管这种方法显示出了前景,但优化 MSC 来源及其传递仍然具有挑战性。本研究旨在测试使用从人类关节镜冲洗液(AFF)中发现的 MSC 来进行软骨再生的可行性,即将其纳入一种新开发的一步快速交联超支化聚 PEGDA/HA 水凝胶中。AFF-MSCs 是从 10 名患者关节镜手术前的关节内冲洗液中分离出来的。水凝胶是由超支化聚 PEGDA 和巯基化透明质酸(HA)制成的。体外试验表明,AFF-MSCs 具有典型的 MSC 形态和表型,并且当包封在水凝胶中时,保持着软骨分化特性。AFF-MSC/水凝胶复合物在植入 8 周后可显著修复大鼠模型中的全层软骨缺损;形成了光滑的软骨,有透明软骨形成的证据。这些数据表明,人 AFF-MSCs 是一种新的、丰富的 MSC 来源,对软骨再生具有很高的治疗价值。
许多尝试已经被用来修复关节软骨的缺陷,包括基于间充质干细胞(MSC)的组织工程策略。优化 MSC 来源及其传递途径仍然具有临床挑战性。最近的研究确定,滑膜和滑液来源的 MSC 表现出更好的软骨形成潜力。然而,尚无可行的方法来获取这些人类组织和细胞,这阻碍了它们的临床应用。在此,我们探索了一种简单、易获取的方法,从关节镜冲洗液(AFF)中获得一种新的干细胞来源,该来源可能包含大量来自滑膜和滑液的 MSC。进一步的实验表明,用一步快速交联的聚 PEGDA/HA 水凝胶包封这些干细胞在软骨再生方面具有非常有希望的潜力。